Baxter Bros Inc Bristol Myers Squibb CO Transaction History

Baxter Bros Inc

$762 Million
Q3 2024

A detailed history of Baxter Bros Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Baxter Bros Inc holds 13,950 shares of BMY stock, worth $812,308. This represents 0.09% of its overall portfolio holdings.

Number of Shares

13,950

Previous 16,204 13.91%

Holding current value

$812,308

Previous $672,000 7.29%

% of portfolio

0.09%

Previous 0.09%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	SELL	$39.66 - $51.75 $89,393 - $116,644	-2,254 Reduced 13.91%	13,950 $721,000
Q2 2024 Jul 15, 2024	SELL	$40.25 - $52.99 $50,473 - $66,449	-1,254 Reduced 7.18%	16,204 $672,000
Q1 2024 Apr 26, 2024	SELL	$47.98 - $54.4 $215,814 - $244,691	-4,498 Reduced 20.49%	17,458 $946,000
Q4 2023 May 17, 2024	BUY	$48.48 - $57.85 $218,063 - $260,209	4,498 Added 25.76%	21,956 $1.13 Million
Q4 2023 Feb 06, 2024	SELL	$48.48 - $57.85 $432,393 - $515,964	-8,919 Reduced 28.89%	21,956 $1.13 Million
Q3 2023 May 17, 2024	BUY	$57.89 - $64.73 $776,710 - $868,482	13,417 Added 76.85%	30,875 $1.79 Million
Q3 2023 Oct 23, 2023	SELL	$57.89 - $64.73 $428,559 - $479,196	-7,403 Reduced 19.34%	30,875 $1.79 Million
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $17,392 - $19,312	-273 Reduced 0.71%	38,278 $2.45 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $52,108 - $59,102	-793 Reduced 2.02%	38,551 $2.67 Million
Q4 2022 Jan 31, 2023	SELL	$68.48 - $81.09 $122,921 - $145,556	-1,795 Reduced 4.36%	39,344 $2.83 Million
Q3 2022 Nov 10, 2022	SELL	$0.13 - $76.84 $8 - $5,301	-69 Reduced 0.17%	41,139 $2.93 Million
Q2 2022 Jul 25, 2022	SELL	$72.62 - $79.98 $104,863 - $115,491	-1,444 Reduced 3.39%	41,208 $3.17 Million
Q1 2022 Apr 20, 2022	SELL	$61.48 - $73.72 $105,376 - $126,356	-1,714 Reduced 3.86%	42,652 $3.12 Million
Q4 2021 Jan 14, 2022	SELL	$53.63 - $62.52 $288,153 - $335,919	-5,373 Reduced 10.8%	44,366 $2.77 Million
Q3 2021 Oct 25, 2021	SELL	$59.17 - $69.31 $73,429 - $86,013	-1,241 Reduced 2.43%	49,739 $2.94 Million
Q2 2021 Aug 11, 2021	SELL	$61.91 - $67.42 $79,863 - $86,971	-1,290 Reduced 2.47%	50,980 $3.41 Million
Q1 2021 Apr 23, 2021	BUY	$59.34 - $66.74 $237,953 - $267,627	4,010 Added 8.31%	52,270 $3.3 Million
Q4 2020 Jan 25, 2021	BUY	$57.74 - $65.43 $168,774 - $191,251	2,923 Added 6.45%	48,260 $2.99 Million
Q3 2020 Nov 05, 2020	BUY	$57.43 - $63.64 $178,492 - $197,793	3,108 Added 7.36%	45,337 $2.73 Million
Q2 2020 Jul 31, 2020	BUY	$54.82 - $64.09 $462,132 - $540,278	8,430 Added 24.94%	42,229 $2.48 Million
Q1 2020 Apr 17, 2020	BUY	$46.4 - $67.43 $688,622 - $1 Million	14,841 Added 78.28%	33,799 $1.88 Million
Q4 2019 Jan 10, 2020	BUY	$49.21 - $64.19 $524,529 - $684,201	10,659 Added 128.44%	18,958 $1.22 Million
Q4 2019 Jan 09, 2020	SELL	$49.21 - $64.19 $453,371 - $591,382	-9,213 Reduced 52.61%	8,299 $490,000
Q3 2019 Oct 21, 2019	SELL	$42.77 - $50.71 $93,880 - $111,308	-2,195 Reduced 11.14%	17,512 $888,000
Q2 2019 Jul 29, 2019	BUY	$44.62 - $49.34 $122,749 - $135,734	2,751 Added 16.22%	19,707 $894,000
Q1 2019 Apr 22, 2019	SELL	$45.12 - $53.8 $48,097 - $57,350	-1,066 Reduced 5.91%	16,956 $809,000
Q4 2018 Jan 22, 2019	SELL	$48.76 - $63.23 $63,192 - $81,946	-1,296 Reduced 6.71%	18,022 $937,000
Q3 2018 Oct 11, 2018	BUY	$55.19 - $62.25 $77,486 - $87,399	1,404 Added 7.84%	19,318 $1.2 Million
Q2 2018 Jul 17, 2018	BUY	$50.53 - $62.98 $12,581 - $15,682	249 Added 1.41%	17,914 $991,000
Q1 2018 May 16, 2018	SELL	$59.92 - $68.98 $65,912 - $75,878	-1,100 Reduced 5.86%	17,665 $1.12 Million
Q4 2017 Feb 01, 2018	BUY	$59.94 - $65.35 $163,696 - $178,470	2,731 Added 17.03%	18,765 $1.15 Million
Q3 2017 Oct 16, 2017	BUY	$55.23 - $63.74 $885,557 - $1.02 Million	16,034	16,034 $1.02 Million

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baxter Bros Inc, based on Form 13F filings with the SEC.

News

Stay updated on Baxter Bros Inc with notifications on news.

Account